| Document and Entity Information | Jul. 14, 2023 |
| Document Information [Line Items] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Document Period End Date | Jul. 14, 2023 |
| Entity Registrant Name | Carmell Corp |
| Entity Incorporation, State or Country Code | DE |
| Entity File Number | 001-40228 |
| Entity Tax Identification Number | 86-1645738 |
| Entity Address, Address Line One | 2403 Sidney Street |
| Entity Address, Address Line Two | Suite 300 |
| Entity Address, City or Town | Pittsburgh |
| Entity Address, State or Province | PA |
| Entity Address, Postal Zip Code | 15203 |
| City Area Code | 919 |
| Local Phone Number | 313-9633 |
| Entity Information, Former Legal or Registered Name | Carmell Therapeutics Corporation1 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
| Amendment Description | This Amendment No. 1 on Form 8-K (“Amendment No. 1”) amends Item 9.01 of the Current Report on Form 8-K filed by Carmell Corporation (the “Company”) on July 20, 2023 (the “Original Report”) in which the Company reported, among other events, the consummation of the Business Combination (as defined in the Original Report). As of the date of the Original Report, the Company’s name was Carmell Therapeutics Corporation. This Amendment No. 1 hereby amends the subsections of Item 2.01 identified below and Item 9.01 in the Original Report to include (i) the unaudited financial statements of Legacy Carmell (as defined in the Original Report) as of and for the six months ended June 30, 2023 and 2022, (ii) the Management’s Discussion and Analysis of Financial Condition and Results of Operations of Legacy Carmell for the six months ended June 30, 2023 and (iii) the unaudited pro forma condensed combined financial information as of and for the six months ended June 30, 2023. This Amendment No. 1 also hereby amends the subsections of Item 5.02 identified below to update certain of the information therein. The text of the Original Report is hereby incorporated by reference. This Amendment No. 1 solely amends the subsections of Item 2.01 and 5.02 identified below, and Item 2.01 and 5.02 of the Original Report otherwise remains unchanged, and Item 9.01 of the Original Report. This Amendment No. 1 does not amend any other item of the Original Report or purport to provide an update or a discussion of any developments at the Company or its subsidiaries subsequent to the filing date of the Original Report. Capitalized terms not otherwise defined herein shall have the respective meanings ascribed to them in the Original Report. |
| Entity Central Index Key | 0001842939 |
| Former Address [Member] | |
| Document Information [Line Items] | |
| Entity Address, Address Line One | 1177 Avenue of the Americas |
| Entity Address, Address Line Two | 5th Floor |
| Entity Address, City or Town | New York |
| Entity Address, State or Province | NY |
| Entity Address, Postal Zip Code | 10036 |
| Common Stock [Member] | |
| Document Information [Line Items] | |
| Title of 12(b) Security | Common Stock, par value $0.0001 per share |
| Trading Symbol | CTCX |
| Security Exchange Name | NASDAQ |
| Warrant [Member] | |
| Document Information [Line Items] | |
| Title of 12(b) Security | Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 |
| Trading Symbol | CTCXW |
| Security Exchange Name | NASDAQ |
